Antibodies to hepatitis B virus surface antigen and survival of hemodialysis patients – a prospective study

References

• United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015. p. 2015.
   Google Scholar
• Świderska M, Mostowska A, Grzegorzewska AE. T helper cell related cytokine gene polymorphisms and vitamin D pathway gene polymorphisms as predictors of survival probability in patients on renal replacement therapy. Pol Arch Med Wewn. 2015;125:511–520.
   PubMed Web of Science ®Google Scholar
• Floege J, Gillespie IA, Kronenberg F, et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015;87:996–1008.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120:1883–1887.
   PubMed Web of Science ®Google Scholar
• Wakasugi M, Kawamura K, Yamamoto S, et al. High mortality rate of infectious diseases in dialysis patients: a comparison with the general population in Japan. Ther Apher Dial. 2012;16:226–231.
   PubMed Web of Science ®Google Scholar
• Edey M, Barraclough K, Johnson DW. Review article: hepatitis B and dialysis. Nephrology (Carlton). 2010;15:137–145.
   PubMed Web of Science ®Google Scholar
• Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial. 2013;26:416–426.
   PubMed Web of Science ®Google Scholar
• Schroth RJ, Hitchon CA, Uhanova J, et al. Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database Syst Rev. 2004;3:CD003775.
   Google Scholar
• Knerr K, Füth R, Hemsen P, et al. Chronic inflammation and hemodialysis reduce immune competence of peripheral blood leukocytes in end-stage renal failure patients. Cytokine. 2005;30:132–138.
   PubMed Web of Science ®Google Scholar
• Bel’eed K, Wright M, Eadington D, et al. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78:538–540.
   PubMed Web of Science ®Google Scholar
• Van Damme P, von Sonnenburg F, Hatz C, et al. Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. J Med Virol. 2009;81:1710–1715.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Pahl MV, Crum A, et al. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22:149–156.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Van Biesen W. Incidence of infectious morbidity and mortality in dialysis patients. Blood Purif. 2002;20:477–480.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.
   PubMed Web of Science ®Google Scholar
• Patel N, Assimon MM, Bruni E, et al. Incidence and clinical predictors of nonresponse to hepatitis B vaccination among patients receiving hemodialysis: importance of obesity. South Med J. 2015;108:567–573.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Martin P, et al. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011;33:815–821.
   PubMed Web of Science ®Google Scholar
• Gracia M, Betriu À, Martínez-Alonso M, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2015. doi:10.2215/CJN.01240215.
   PubMed Web of Science ®Google Scholar
• Lee CC, Wu CJ, Chou LH, et al. Peripheral artery disease in peritoneal dialysis and hemodialysis patients: single-center retrospective study in Taiwan. BMC Nephrol. 2012;13:100.
   PubMed Web of Science ®Google Scholar
• Mathew RO, Mason DL, Song R, et al. Role of T-regulatory cells in the response to hepatitis B vaccine in hemodialysis patients. Hemodial Int. 2015. doi:10.1111/hdi.12326.
   PubMed Web of Science ®Google Scholar
• Fernández E, Betriu MA, Gómez R, et al. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996;11:1559–1563.
   PubMed Web of Science ®Google Scholar
• Afsar B. The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients. Nephrourol Mon. 2013;5:806–812.
   PubMedGoogle Scholar
• Morgan MD, Richter A, Al-Ali S, et al. Low B cells and IgG are associated with infection, while poor vaccine response predicts all-cause mortality in an immunosuppressed vasculitis population. Arthritis Care Res (Hoboken). 2015; doi:10.1002/acr.22757.
   Google Scholar
• Lin SY, Liu JH, Wang SM, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol. 2012;13:97.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines. 2014;13:1317–1326.
   PubMed Web of Science ®Google Scholar
• Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63:2222–2229.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun J, Zhu B, et al. Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. Ren Fail. 2010;32:1255–1264.
   PubMed Web of Science ®Google Scholar
• Rutkowski B, Lichodziejewska-Niemierko M, Grenda R, et al. Report on renal replacement therapy in Poland – 2010. Gdańsk, Drukonsul. 2013; 30 pp.
   Google Scholar
• Kim AJ, Lee JH, Ko KP, et al. Outcomes of hepatitis B surface antigenemia in patients with incident end-stage renal disease. Nephrology (Carlton). 2015. doi:10.1111/nep.12687.
   Google Scholar
• Kwon E, Cho JH, Jang HM, et al. Clinical Research Center for End Stage Renal Disease (CRC for ESRD) investigators: differential effect of viral hepatitis infection on mortality among Korean maintenance dialysis patients: A prospective multicenter cohort study. PLoS One. 2015;10:e0135476.
   Google Scholar
• Lowrie EG, Lew NL, Huang WH. Race and diabetes as death risk predictors in hemodialysis patients. Kidney Int Suppl. 1992;38:S22–31.
   Google Scholar
• Charytan D, Kuntz RE, Mauri L, et al. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;49:409–416.
   PubMed Web of Science ®Google Scholar
• Tepel M, Armbruster FP, Grön HJ, et al. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab. 2013;98:4744–4751.
   PubMed Web of Science ®Google Scholar
• Jean G, Lataillade D, Genet L, et al. ARNOS study investigators: association between very low PTH levels and poor survival rates in haemodialysis patients: results from the French ARNOS cohort. Nephron Clin Pract. 2011;118:c211–16.
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR–16):1–33.
   PubMedGoogle Scholar
• Hasegawa T, Bragg-Gresham JL, Yamazaki S, et al. Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol. 2009;4:595–602.
   PubMed Web of Science ®Google Scholar
• Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004; 65:2335–2342.
   PubMed Web of Science ®Google Scholar
• Kim HW, Kim SH, Kim YO, et al. The impact of high-flux dialysis on mortality rates in incident and prevalent hemodialysis patients. Korean J Intern Med. 2014;29:774–784.
   PubMed Web of Science ®Google Scholar
• Al Saran K, Sabry A, Al Halawany Z, et al. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014;25:185–191.
   PubMedGoogle Scholar
• Jadoul M, Goubau P. Is anti-hepatitis B virus immunization successful in elderly hemodialysis patients? Clin Nephrol. 2002;58:301–304.
   PubMed Web of Science ®Google Scholar
• Ibrahim S, El-Din S, Bazzal I. Antibody level after hepatitis-B vaccination in hemodialysis patients: impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status. J Natl Med Assoc. 2006;98:1953–1957.
   PubMed Web of Science ®Google Scholar
• Saffar H, Saffar MJ, Ajami A, et al. Long-term T-cell-mediated immunologic memory to hepatitis B vaccine in young adults following neonatal vaccination. Hepat Mon. 2014;14:e22223.
   Google Scholar
• Michalak TI, Pasquinelli C, Guilhot S, et al. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest. 1994;93:230–239.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–1108.
   PubMed Web of Science ®Google Scholar
• Ferrari C. HBV and the immune response. Liver Int. 2015;35(Suppl 1):121–128.
   PubMed Web of Science ®Google Scholar
• Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines. 2014;13:285–298.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20:440–451.
   PubMed Web of Science ®Google Scholar
• Kim KW, Chung BH, Jeon EJ, et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012;44:465–472.
   PubMed Web of Science ®Google Scholar
• Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–1226.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78:5535–5545.
   PubMed Web of Science ®Google Scholar
• Platt A, Wetzler L. Innate immunity and vaccines. Curr Top Med Chem. 2013;13:2597–608.
   PubMed Web of Science ®Google Scholar
• Wang C, Tang J, Song W, et al. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39:978–988.
   PubMed Web of Science ®Google Scholar
• Pol S, Legendre C, Mattlinger B, et al. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990;11:385–387.
   PubMed Web of Science ®Google Scholar
• Höhler T, Stradmann-Bellinghausen B, Starke R, et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol. 2002;37:387–392.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Wobszal PM, Mostowska A, et al. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol. 2012;13:75. doi:10.1186/1471-2369-13-75.
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Z, Lu F, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine. 2011;29:706–711.
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Jodłowska E, Mostowska A, et al. Single nucleotide polymorphisms of vitamin D binding protein, vitamin D receptor and retinoid X receptor alpha genes and response to hepatitis B vaccination in renal replacement therapy patients. Expert Rev Vaccines. 2014;13:1395–1403.
   PubMed Web of Science ®Google Scholar